Indications |
Oral Type 2 diabetes mellitus Adult: Initially, 40-80 mg daily gradually increased to 320 mg daily if necessary. Doses >160 mg daily may be given in 2 divided doses. For modified release tab: Initially, 30 mg once daily, may increase up to 120 mg daily. |
Contraindications |
Type 1 DM, diabetes complicated with ketoacidosis; hypersensitivity; severe renal and hepatic impairment. Pregnancy and lactation. |
Warnings / Precautions |
Monitor blood glucose concentration. May require insulin during metabolic stress. Care when transferring from combination therapy. Increased risk of severe hypoglycaemia in elderly, debilitated patients, patients with hepatic or renal impairment. Risk of hypogylcaemia when caloric intake is deficient, after strenuous exercise, when taken with ethanol or when >1 antidiabetic drug is used. |
Adverse Reactions |
GI disturbances, skin reaction, leucopenia, thrombocytopenia, agranulocytosis, haemolytic anaemia, cholestatic jaundice, vomiting, diarrhoea, gastritis, increased transaminases. |
Drug Interactions |
Nausea and flushing with alcohol. Hypoglycaemic effect increased by salicylates, phenylbutazone, clofibrate, sulphonamides, oral anticoagulants and MAOIs. Hypoglycaemic effect diminished by rifampicin, barbiturates, alcohol, diuretics, diazoxide, corticosteroids, β-blockers, oestrogens and sympathomimetic drugs; dose adjustment may be required. See Below for More gliclazide Drug Interactions |
Mechanism of Actions |
Gliclazide stimulates insulin secretion from pancreatic β-cells, reduces hepatic gluconeogenesis, and lowers blood glucose concentrations. It also inhibits platelet aggregation at therapeutic doses. Duration: ≥12 hr. Absorption: Readily absorbed from the GI tract (oral). Distribution: Protein-binding: 94%. Metabolism: Extensively hepatic; converted to inactive metabolites. Excretion: Urine (60-70% metabolites and small amounts of unchanged drug); faeces (10-20%); 10-12 hr (elimination half-life). |
Administration |
Should be taken with food. |
ATC Classification |
A10BB09 - gliclazide ; Belongs to the class of sulfonamides, urea derivatives. Used in the treatment of diabetes. |
Available As |
|
Gliclazide
Post Review about Gliclazide Click here to cancel reply.
Gliclazide Containing Brands
Gliclazide is used in following diseases
Drug - Drug Interactions of Gliclazide
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.